Etzer Darout, an analyst from BMO Capital, reiterated the Buy rating on C4 Therapeutics (CCCC – Research Report). The associated price target is $20.00.
Etzer Darout has given his Buy rating due to a combination of factors related to C4 Therapeutics’ promising clinical developments and strategic plans. The company is on track with its clinical updates for its lead programs, particularly cemsidomide, which is being developed for multiple myeloma and peripheral T-cell lymphoma. The anticipated updates in the second half of 2025 are expected to inform the next steps in development, presenting a potential value opportunity for investors.
Additionally, C4 Therapeutics is advancing its CFT1946 program, targeting BRAF V600 mutations, with promising early data. The completion of Phase 1 trials and the presentation of data in the latter half of 2025 could serve as a significant inflection point. The company’s financial position, with substantial cash reserves, supports its ongoing research and development efforts, further justifying the Buy rating.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target.